Literature DB >> 22122281

Histone methylation in myelodysplastic syndromes.

Yue Wei1, Irene Gañán-Gómez, Sophie Salazar-Dimicoli, Sara L McCay, Guillermo Garcia-Manero.   

Abstract

Histone methylation is a type of epigenetic modification that is critical for the regulation of gene expression. Numerous studies have demonstrated that abnormalities of this newly characterized epigenetic modification are involved in the development of multiple diseases, including cancer. There is also emerging evidence for a link between histone methylation and the pathogenesis of myeloid neoplasms, including myelodysplastic syndromes (MDS). This article provides an overview of recent progress in the studies of histone methylation in myeloid malignancies, with an emphasis on MDS. We cover each type of histone methylation modification and their regulatory mechanisms, as well as their abnormalities in MDS or potential connections to MDS. We also summarize the recent progress in the development of inhibitors targeting histone methylation and their applications as potential therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22122281      PMCID: PMC3758889          DOI: 10.2217/epi.11.9

Source DB:  PubMed          Journal:  Epigenomics        ISSN: 1750-192X            Impact factor:   4.778


  118 in total

1.  Histone demethylation by a family of JmjC domain-containing proteins.

Authors:  Yu-ichi Tsukada; Jia Fang; Hediye Erdjument-Bromage; Maria E Warren; Christoph H Borchers; Paul Tempst; Yi Zhang
Journal:  Nature       Date:  2005-12-18       Impact factor: 49.962

2.  Molecular Pathogenesis of MDS.

Authors:  A Thomas Look
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2005

Review 3.  Unraveling the molecular pathophysiology of myelodysplastic syndromes.

Authors:  Rafael Bejar; Ross Levine; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

4.  Hypermethylation of the p15INK4B gene in myelodysplastic syndromes.

Authors:  T Uchida; T Kinoshita; H Nagai; Y Nakahara; H Saito; T Hotta; T Murate
Journal:  Blood       Date:  1997-08-15       Impact factor: 22.113

5.  Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain.

Authors:  Qin Feng; Hengbin Wang; Huck Hui Ng; Hediye Erdjument-Bromage; Paul Tempst; Kevin Struhl; Yi Zhang
Journal:  Curr Biol       Date:  2002-06-25       Impact factor: 10.834

6.  Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

Authors:  Véronique Gelsi-Boyer; Virginie Trouplin; José Adélaïde; Julien Bonansea; Nathalie Cervera; Nadine Carbuccia; Arnaud Lagarde; Thomas Prebet; Meyer Nezri; Danielle Sainty; Sylviane Olschwang; Luc Xerri; Max Chaffanet; Marie-Joëlle Mozziconacci; Norbert Vey; Daniel Birnbaum
Journal:  Br J Haematol       Date:  2009-04-15       Impact factor: 6.998

7.  Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.

Authors:  Guillermo Garcia-Manero; Sarit Assouline; Jorge Cortes; Zeev Estrov; Hagop Kantarjian; Hui Yang; Willie M Newsome; Wilson H Miller; Caroline Rousseau; Ann Kalita; Claire Bonfils; Marja Dubay; Tracy-Ann Patterson; Zuomei Li; Jeffrey M Besterman; Gregory Reid; Eric Laille; Robert E Martell; Mark Minden
Journal:  Blood       Date:  2008-05-21       Impact factor: 22.113

8.  NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis.

Authors:  Gang G Wang; Ling Cai; Martina P Pasillas; Mark P Kamps
Journal:  Nat Cell Biol       Date:  2007-06-24       Impact factor: 28.824

9.  PHF8 mediates histone H4 lysine 20 demethylation events involved in cell cycle progression.

Authors:  Wen Liu; Bogdan Tanasa; Oksana V Tyurina; Tian Yuan Zhou; Reto Gassmann; Wei Ting Liu; Kenneth A Ohgi; Chris Benner; Ivan Garcia-Bassets; Aneel K Aggarwal; Arshad Desai; Pieter C Dorrestein; Christopher K Glass; Michael G Rosenfeld
Journal:  Nature       Date:  2010-07-11       Impact factor: 49.962

10.  Protein arginine-methyltransferase-dependent oncogenesis.

Authors:  Ngai Cheung; Li Chong Chan; Alex Thompson; Michael L Cleary; Chi Wai Eric So
Journal:  Nat Cell Biol       Date:  2007-09-23       Impact factor: 28.824

View more
  2 in total

1.  Nuclear Receptors in Drug Metabolism, Drug Response and Drug Interactions.

Authors:  Chandra Prakash; Baltazar Zuniga; Chung Seog Song; Shoulei Jiang; Jodie Cropper; Sulgi Park; Bandana Chatterjee
Journal:  Nucl Receptor Res       Date:  2015

2.  BMI1 reprogrammes histone acetylation and enhances c-fos pathway via directly binding to Zmym3 in malignant myeloid progression.

Authors:  Hongjie Shen; Zixing Chen; Xin Ding; Xiaofei Qi; Jiannong Cen; Yuanyuan Wang; Li Yao; Yan Chen
Journal:  J Cell Mol Med       Date:  2014-02-27       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.